BCBS Louisiana Medical Policy Updates – August 2018

August 2018 BCBS Louisiana Medical Policy Updates:

• abaloparatide (Tymlos)
• Actigraphy
• Auditory Brainstem Implant
• Autoinjectable Methotrexate (Otrexup)
• Biventricular Pacemakers (Cardiac Resynchronization Therapy) for the Treatment of Heart Failure
• Cardiac Hemodynamic Monitoring for the Management of Heart Failure in the Outpatient Setting
• Circulating Tumor DNA and Circulating Tumor Cells for Cancer Management (Liquid Biopsy)
• ecallantide (Kalbitor)
• Endovascular Therapies for Extracranial Vertebral Artery Disease
• Enhanced External Counterpulsation (EECP)
• Extracranial Carotid Angioplasty/Stenting
• Genetic Testing for Duchenne and Becker Muscular Dystrophy
• Genetic Testing for Heterozygous Familial Hypercholesterolemia
• Genetic Testing for Lactase Insufficiency
• Genetic Testing for Limb-Girdle Muscular Dystrophies
• Genotyping for 9p21 Single Nucleotide Polymorphisms to Predict Risk of Cardiovascular Disease or Aneurysm
• GLP-1 Agonists for Diabetes
• Hematopoietic Stem-Cell Transplantation for Solid Tumors of Childhood
• Implantable Sinus Stents for Postoperative Use Following Endoscopic Sinus Surgery and for Recurrent Sinus Disease
• interferon beta 1-b (Betaseron)
• Low-Level Laser Therapy
• Mechanical Stretch Devices for Joint Stiffness and Contractures
• metreleptin (Myalept)
• Microwave Tumor Ablation
• Myoelectric Prosthetic Components for the Upper Limb
• Neurodiagnostics
• Opioid Management/Long Acting Oral Opioid Step Therapy
• Overactive Bladder Medications (Branded)
• pegloticase (Krystexxa)
• Peripheral Subcutaneous Field Stimulation
• Pharmacogenetic Testing for Pain Management
• Postsurgical Home Use of Limb Compression Devices for Venous Thromboembolism Prophylaxis
• Prolotherapy
• Radiofrequency Ablation of Miscellaneous Solid Tumors Excluding Liver Tumors
• reslizumab (Cinqair)
• Select Drugs for Attention Deficit Hyperactivity Disorder (ADHD)
• Skin Contact Monochromatic Infrared Energy as a Technique to Treat Cutaneous Ulcers, Diabetic Neuropathy, and Miscellaneous Musculoskeletal Conditions
• Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitors and Combination Products
• teduglutide [rDNA origin] (Gattex)
• Topical Corticosteroids
• vedolizumab (Entyvio)

Click here to view the Blue Cross Blue Shield Louisiana Medical Policy Updates »

Policy Alerts monitors Commercial and Medicare medical policies for changes. While medical Insurance carriers typically update medical policies annually, there are many reasons why they might review or update a policy. When reviews occur out of cycle they often go unnoticed. Policy Alerts keeps you updated when Payers make coverage changes to medical policies affecting your business.

Policy Alerts continuously monitors Commercial and Medicare Payer coverage information to keep you up-to-date on medical Insurance decisions in real-time. When changes occur, instant email alerts are delivered to your inbox. Clients have access to detailed coverage reports and medical policies through the interactive Policy Alerts Dashboard portal. Save time each month and keep focused on important Payer medical policy reviews and coverage decisions affecting your business!

Policy Alerts takes a client-focused hands-on approach and is constantly working to provide our customers with helpful insights and actionable analytics. We understand what our clients need and are dedicated to providing timely, accurate, and always up-to-date reports.

Health economic and reimbursement information provided by Policy Alerts is gathered from third-party sources and is subject to change without notice as a result of complex and frequently changing laws, regulations, rules and policies. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them. This information is presented for illustrative purposes only and does not constitute reimbursement or legal advice.